Insight Molecular Diagnostics Inc. (IMDX) stock: price, suppliers, customers and institutional ownership
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies. The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
the bull case· 2
40
managers reporting a position in thirteen f filings
13fJun 30 '26+4.24%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26the bear case· 2
2
managers whose positions together make up four fifths of the reported value
13fJun 30 '266 of 18
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Nov 12 '26 report. Not a forecast, not advice.
Insight Molecular Diagnostics Inc. has no measured co-movers clearing our correlation floor, so only its SEC classification is shown.
SIC 2835, In Vitro & In Vivo Diagnostic Substances, from each company's own filings. Largest first.
Insight Molecular Diagnostics Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · In Vitro & In Vivo Diagnostic Substances
High 4.02 at 3:00 pm ET, low 3.80 at 11:00 am ET.
tall tick = annual report · 1 on record
IMDX (Insight Molecular Diagnostics Inc.) has 2 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.
40 managers report a position worth $108.9M between them, and 2 of them hold 80% of it.